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Abstract:

2

Purpose: To evaluate the effectiveness of focal laser for treatment of diabetic macular edema (DME)

3

performed by ophthalmology residents.

4

Methods: Chart review of DME patients treated in a resident clinic with focal laser. Visual acuity (VA),

5

OCT central subfield thickness (CST), and maximum subfield thickness (MST) at initial, 1 month, and 6

6

month visits were recorded.

7

Results: For 32 reviewed patients, average VA was 20/58 initially and 20/39 at 6 months (p=0.18). Mean

8

CST was 311 µm initially and 305 µm at 6 months (p=0.09). Mean MST was 413 µm initially and 382

9

µm at 6 months (p=0.007). Factors favoring success are: initial CST <400 µm, treatment of localized

10

microaneurysms, and prior focal laser treatments.

11

Conclusion: Focal laser performed by residents was effective in decreasing MST and maintained visual

12

acuity. Initial CST, localized microaneurysms and repeat focal treatment predicted improved outcomes.
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Introduction
Diabetic macular edema (DME) is the most common cause of vision loss in diabetic retinopathy.1

28

It is a prevalent disease, affecting 7% of people with diabetes.2 The mechanism for edema in diabetic

29

retinopathy is due to abnormal vascular permeability.3 As in diabetic retinopathy, the greatest modifiable

30

risk factor for the development of DME is hyperglycemia.4 DME is diagnosed by the presence of macular

31

thickening observed via slit lamp biomicroscopy, stereoscopic fundus photos, or on optical coherence

32

tomography (OCT) (figure 1). Other exam findings such as hard exudates in the presence of

33

microaneurysms and blot hemorrhages within one disc diameter of the fovea have been utilized for

34

diagnosis as well.4 Fluorescein angiography (FA) can also aid in diagnosis. It will show vascular leakage

35

in the setting of edema, which frequently correlates well with OCT findings.5

36

Treatment of DME, with goals of immediate and sustained visual improvement and prevention of

37

vision loss, has evolved through the years. The first available treatment option began in 1985 when the

38

Early Treatment Diabetic Retinopathy Study established the effectiveness of laser photocoagulation for

39

DME.6 Laser can be performed in focal pattern, targeting specific leaking microaneurysms, or in a grid

40

pattern to target areas of more diffuse leakage.6 Our study concentrates on focal laser photocoagulation.

41

While laser was the only treatment option available for 20 years, there are now several other

42

modalities available. The advent of intravitreal anti-vascular endothelial growth factor (VEGF)

43

medications, beginning with pegaptanib in 2005 introduced a second treatment option, particularly useful

44

for center-involving DME that is not amenable to laser treatment.7 Currently, ranibizumab, aflibercept,

45

and the off-label use of bevacizumab, are available anti-VEGF agents, and these agents have dramatically

46

changed the treatment of DME. The release of the Diabetic Retinopathy Clinical Research Network

47

(DRCR.net) Protocol I data, demonstrated the role of intravitreal anti-VEGF agents in combination with

48

focal/grid laser treatment.8

49

There are additional treatment options that may be utilized, particularly in refractory cases. This

50

includes intravitreal triamcinolone, which was superior to laser alone in pseudophakic eyes when studied

51

in DRCR.net protocol I, as well as various other ocular steroid formulations.9 Lastly, DME that is

3

52

associated with posterior hyaloid traction and/or epiretinal membrane may be amenable to improvement

53

with pars plana vitrectomy.10

54

Given the multitude of treatment options and various treatment algorithms that have been studied,

55

the decision for when focal laser is indicated is very practitioner-dependent and frequently based on

56

personal experience. Our study analyzes focal laser treatments performed by multiple physicians in an

57

inner-city population to identify patient selection factors and treatment parameters that correlated with

58

successful outcomes.

59
60
61

Methods
Patients with DME were selected from outpatient visits with multiple physicians at Parkland

62

Memorial Hospital (Dallas, TX). The study was conducted in accordance with the World Medical

63

Association Declaration of Helsinki.

64

The study consisted of 32 patients, 24 (75%) of which were male. The population was

65

predominantly Hispanic (59.4%), and the average age was 65 years old. Average hemoglobin A1c was

66

8.3%. See table 1 for additional demographic characteristics.

67

Patient selection for receiving focal laser treatment was physician dependent, and these selection

68

factors were analyzed in the study. Exclusion criteria included macula edema not secondary to diabetic

69

retinopathy (e.g. retinal vein occlusion, Irvine-Gass Syndrome, uveitic macular edema), lack of return for

70

the 1 month follow-up appointment, or if pre-treatment or post-treatment OCT’s (Heidelberg Spectralis)

71

were not available.

72

For each selected patient, laser treatment was performed with an Iridex 532 nm green laser

73

through a slit-lamp delivery system in single spots without pattern scanning. The lens used for all

74

treatments was a Volk Area Centralis contact lens. Treatment parameters including laser power and

75

duration settings, spot size, number of shots, and pattern of treatment were analyzed.

76
77

Patients returned for 1-month follow-up, with the primary outcomes examined at that visit
including visual acuity change, OCT central subfield thickness (CST) change, and maximal subfield

4

78

thickness (MST) change as compared to pre-treatment values. MST was analyzed because the goal of

79

many focal laser treatments was to target a non-central area of leakage in order to prevent future central

80

involvement.

81
82
83

Results
Visual acuity was recorded on logMAR scale, with a pre-treatment average visual acuity of 0.42

84

(corresponding to 20/52) and 1-month post treatment average visual acuity of 0.34 (corresponding to

85

20/44). The average CST was 322.26 µm pre-treatment and 325.81 µm post-treatment, while the average

86

MST did improve marginally from 418.29 µm to 407.74 µm. Average laser parameters used were

87

96.78mW power, 0.1 second duration, 91.38 µm spot size, and shot count of 4.43.

88

When comparing patients with less than 400 µm CST (n = 57) pre-treatment to patients with

89

greater than 400 µm (n = 10), there was a statistically significant (p = 0.0001) difference in CST change

90

and MST change at 1 month, favoring those patients with thinner pre-treatment CST. This is attributable

91

to the fact that in eyes with CST greater than 400 µm, significant amount of the leakage was centrally

92

located and was not amenable to focal laser. This OCT improvement did not, however, correlate with

93

statistically significant visual acuity improvement advantage for those with less than 400 µm pre-

94

treatment. See Table 2 for detailed study results.

95

Conclusions

96

For patients who had less than 5 microaneurysms targeted with laser treatment, there was a

97

statistically significant difference in visual acuity, CST, and MST outcomes at 1 month as compared to

98

other targets of treatment. In those patients with fewer microaneurysms targeted, the source of leakage

99

was more focal and therefore responded better to laser treatment.

100

Due to limited resources at our county hospital, FA was only able to be obtained prior to laser

101

treatment in 1/3 of the cases where the source of leakage was uncertain (i.e. many candidate

102

microaneurysms), but there was no significant relationship found between visual acuity or OCT outcomes

103

at 1 month whether the patient had an FA conducted prior to treatment or not.

5

104

Laser parameters were evaluated, and patients were found to have worse outcomes when power

105

settings outside the range of 80-100 mW were utilized, with worse visual acuity, CST, and MST

106

outcomes at 1 month (p = 0.039, 0.022, and 0.014, respectively), as compared to those treatments

107

conducted within the 80-100 mW range. This is likely due to laser power of less than 80 mW being

108

inadequate to sufficiently coagulate microaneurysms or induce significant local photo-chemical changes,

109

and power greater than 100 mW likely inducing more local inflammatory changes which temporarily

110

worsened the swelling at 1 month.

111
112
113

Visual acuity outcomes at 1 month were worse for patients who had previous focal or grid laser
treatment prior to this study as compared to those who had no prior laser (p = 0.07).
There was no significant correlation found between hemoglobin A1c level and visual acuity,

114

CST, or MST outcomes at 1 month follow up. There was also no correlation found between number of

115

intravitreal bevacizumab (Avastin) injections received in the previous 6 months and post-laser

116

outcomes.

117

Overall, focal laser photocoagulation for DME in an inner-city county hospital population

118

improved visual acuity and stabilized macular swelling at 1 month post-treatment. Predictive factors for

119

favorable focal laser outcomes included pre-treatment CST of less than 400 µm, treatment targeting fewer

120

than 5 microaneurysms in a focal area of swelling, and using laser parameters of power between 80 mW

121

and 100 mW. Prior fluorescein angiography, prior macular laser treatments, and hemoglobin A1c

122

percentage did not correlate with improvement at 1 month.
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156

Figure legends

157

Figure 1 - OCT images from a patient who received focal grid laser treatment. 1A - pre-treatment image

158

with temporal macular edema. 1B - 1 month post-treatment image with improved temporal macular

159

edema.
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